Skip to main content
Top
Published in:

Open Access 09-05-2024 | Human Papillomavirus | Research

The prevalence of human papillomavirus in ocular surface squamous neoplasia in HIV positive and negative patients in a South African population

Authors: Loren N. Odendaal, Corinna Andreae, Micheline Sanderson-November, Dan Zaharie, Derrick P. Smit

Published in: Infection | Issue 4/2024

Login to get access

Abstract

Purpose

To assess the prevalence and subtypes of Human Papillomavirus (HPV) in Ocular Surface Squamous Neoplasia (OSSN) in Human Immunodeficiency Virus (HIV) positive and negative patients in South Africa.

Basic procedures

This study was a single center retrospective cross-sectional study, conducted at Tygerberg Hospital, Western Cape, South Africa. We assessed 63 histopathologically confirmed OSSN formalin-fixed paraffin-embedded (FFPE) tissue blocks from 2015–2023. The presence of HPV was determined using the Hybrispot Direct Flow Chip Kit. Corresponding clinical data was retrieved from the National Health Laboratory Service (NHLS) central data warehouse.

Main findings

Of the confirmed OSSN samples, 66.7% tested positive for HPV (95% confidence interval [CI] 54–77.3%). Of the 42 HPV positive samples, 38 (90.5%) had one or more known genotypes detected and 4 had unknown genotypes. The most prevalent subtypes were HPV 11, 16 and 18 (found in 61.9%, 52.4% and 33.3% of HPV positive samples respectively). 88.9% of the lesions biopsied were from HIV positive patients, of whom 56.4% had a CD4 + count of < 200 cells/µL. A lower median CD4 + count was detected among HIV positive patients with invasive squamous cell carcinoma compared to those with moderate dysplasia (p < 0.0198).

Conclusions

There is a high prevalence of HPV in OSSN in South Africa. Certain subtypes namely, 11, 16, 18, 31, 33 and 35 may be more carcinogenic. HIV with HPV co-infection may be linked as a causative factor in the development of OSSN.
Literature
4.
go back to reference Bowling B. Ocular tumours. In: Boling B, editor. Kanski's clinical ophthalmology: a systematicapproach. 8th ed. Elsevier; 2016. p. 476–7. Bowling B. Ocular tumours. In: Boling B, editor. Kanski's clinical ophthalmology: a systematicapproach. 8th ed. Elsevier; 2016. p. 476–7.
18.
go back to reference CDC (2021) HPV Vaccination: What Everyone Should Know | CDC. (Centros para el Control y la Prevención de Enfermedades). CDC (2021) HPV Vaccination: What Everyone Should Know | CDC. (Centros para el Control y la Prevención de Enfermedades).
Metadata
Title
The prevalence of human papillomavirus in ocular surface squamous neoplasia in HIV positive and negative patients in a South African population
Authors
Loren N. Odendaal
Corinna Andreae
Micheline Sanderson-November
Dan Zaharie
Derrick P. Smit
Publication date
09-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02289-8

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar